Deep venous thrombosis: A new task for primary health care - A randomised economic study of outpatient and inpatient treatment

Scandinavian Journal of Primary Health Care

Volumn 22, Issue 1, 2004, Pages 44-49

  Bäckman, Karin ^a   Carlsson, Per ^a   Kentson, Magnus ^b   Hansen, Sören ^c   Engquist, Leif ^d   Hallert, Claes ^e  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Jonkoping Hospital   (Sweden)

^c Eksjo Hospital   (Sweden)

^d Varnamo Hospital   (Sweden)

^e Såpkullen Health Care Centre   (Sweden)

Author keywords

Ambulatory care; Costs and cost analysis; Low molecular weight heparin; Primary health care; Venous thrombosis

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ABSENTEEISM; ARTICLE; BODY WEIGHT; COST; DEEP VEIN THROMBOSIS; HEALTH CARE; HEALTH CENTER; HEALTH ECONOMICS; HOSPITAL PATIENT; HUMAN; MOLECULAR WEIGHT; OUTPATIENT CARE; PRIMARY HEALTH CARE; RANDOMIZATION; SWEDEN;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DALTEPARIN; DIRECT SERVICE COSTS; FEMALE; HEALTH CARE COSTS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; SWEDEN; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 11144358553     PISSN: 02813432     EISSN: None     Source Type: Journal    
DOI: 10.1080/02813430310003543     Document Type: Article

References (17)

1. Martineau P, Tawil N. Low-molecular-weight heparins in the treatment of deep-vein thrombosis. Ann Pharmacother 1998;32:588-98, 601.
2. Hull RD, Raskob GE, Pineo GF, Green SD, Throwbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
3. Hull RD, Raskob GE, Rosenloom D, Pineo GF, Lerner RG, Gafni A, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med 1997;157:289-94.
4. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
5. Hallert C, Blomqvist K. Förenklad trombosbehandling i öppen vård. Lågmolekylärt heparin subkutant i en daglig dos (Simplified thrombosis treatment in outpatient care. Low-molecular-weight heparin subcutaneously in a daily dose). Läkartidningen 1995;92:3011-3.
6. Lindmarker P, Holmstöm M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. J Intern Med 1996;240:395-401.
7. van den Belt AGM, Bossuyt PMM, Prins MH, Gallus AS, Büller HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis: an economic evaluation. Thromb Haemost 1998;79:259-63.
8. Roger M, Bredeson C, Wells PS, Beck J, Kearns B, Huebsch LB. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ 1998;159:931-8.
9. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparin compared with unfractionated heparin for acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999;130:789-99.
10. Dunn AS, Schechter C, Gotlin A, Vomvolakis D, Jacobs E, Sacks H, et al. Outpatient treatment of deep venous thrombosis in diverse inner-city patients. Am J Med 2001;110:458-62.
11. Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000;160:2926-32.
12. Kentson M, Hallert C, Engquist L, Hansen S, Bäckman K, Carlsson P. Randomised study comparing treatment of deep venous thrombosis outside hospital with inpatient hospital treatment using once-daily subcutaneous dalteparin. I. Health-related quality of life. Haemostasis 2000;30(Suppl 1):6.
13. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979;300:1242-5.
14. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-73.
15. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inform J 1991;25:411-24.
16. The National Board of Health and Welfare. The Swedish Hospital Discharge Register 1996. Stockholm, 1999.
17. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized controlled trials. Ann Intern Med 1999;130:800-9.